Ciliate Host Cell Expression for Antibody Glycosylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current systems for producing monoclonal antibodies, such as E. coli and mammalian cell lines, face limitations including inadequate ADCC, incorrect protein folding, hyperglycosylation, high production costs, and susceptibility to viral infections, which hinder the production of antibodies with enhanced ADCC, CDC, and extended serum half-life.
Innovation Solution
A ciliate host cell system is developed for heterologous expression of monoclonal antibodies, utilizing codon-optimized nucleic acid molecules that encode for antibodies or fragments, allowing for secretion and production of full IgG antibodies with an essentially fucose-free N-glycan structure, enhancing ADCC and serum half-life, and eliminating viral contamination risks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If E. coli is used for antibody production, then production cost is reduced, but ADCC activity is insufficient and protein folding is incorrect
Solution Approach 1:
The patent segments the antibody production process by separating the expression host function from the glycosylation function. E. coli expresses the antibody polypeptide chains, while a eukaryotic microorganism provides the glycosylation capability. This segmentation allows each organism to perform its optimal function, resolving the contradiction between low-cost production and high ADCC activity.
Solution Approach 2:
The patent introduces an intermediary system - a eukaryotic microorganism that provides glycosylation enzymes and factors. This intermediary bridges the gap between E. coli's low-cost production capability and the need for proper antibody glycosylation to achieve high ADCC activity. The glycosylated antibody fragments are then purified and reassembled.
2Reliability
If mammalian cell lines are used for antibody production, then ADCC activity is improved, but production cost increases and viral contamination risk arises
Solution Approach 1:
The patent uses a eukaryotic microorganism as a disposable, cost-effective alternative to expensive mammalian cell lines. The microorganism provides necessary glycosylation functions without the high production costs and viral contamination risks associated with mammalian systems. After use, the microbial system can be discarded or recycled without the long-term maintenance costs of mammalian cell banks.
3Duration of action of moving object
If hyperglycosylation occurs in antibody production, then serum half-life is extended, but ADCC activity is reduced
Solution Approach 1:
The patent precisely controls the glycosylation parameters by using a eukaryotic microorganism that adds only the required N-acetylglucosamine residues without excessive glycosylation. This parameter control ensures optimal serum half-life extension while maintaining high ADCC activity, resolving the contradiction between these two opposing effects.
Data Source
AI summary
The present invention is related to a system for the heterologous expression of a monoclonal Antibody (mAb) or a fragment or derivative thereof, said system comprising at least one ciliate host cell, and incorporated, into said ciliate host cell, at least one heterologous nucleic acid molecule encoding for said monoclonal Antibody, or a fragment or derivative thereof.